Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amit M Oza

Showing results (81-90 of 250) with videos related to

Pageof 25
Sort By:
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 19, 2019
FIGO 2018 stage IB2 (2-4 cm) Cervical cancer treated with Neo-adjuvant chemotherapy followed by fertility Sparing Surgery (CONTESSA); Neo-Adjuvant Chemotherapy and Conservative Surgery in Cervical Cancer to Preserve Fertility (NEOCON-F). A PMHC, DGOG, GCIG/CCRN and multicenter studyMarie Plante, Nienke van Trommel, Stephanie Lheureux, et al.
Investigational New Drugs|March 15, 2011
A phase II trial of the Src kinase inhibitor saracatinib (AZD0530) in patients with metastatic or locally advanced gastric or gastro esophageal junction (GEJ) adenocarcinoma: a trial of the PMH phase II consortiumHelen J Mackay, Heather J Au, Elaine McWhirter, et al.
Anti-Cancer Drugs|December 1, 2005
Phase I trial of gemcitabine, doxorubicin and cisplatin (GAP) in patients with advanced solid tumorsIgnacio Duran, Lillian L Siu, Eric X Chen, et al.
Gynecologic Oncology Reports|March 15, 2021
Can <i>TP53</i> variant negative be high-grade serous ovarian carcinoma? A case seriesLawrence Kasherman, Swati Garg, Nairi Tchrakian, et al.
Current Oncology (Toronto, Ont.)|June 23, 2022
A Pan-Canadian Consensus Statement on First-Line PARP Inhibitor Maintenance for Advanced, High-Grade Serous and Endometrioid Tubal, Ovarian, and Primary Peritoneal CancersAnna V Tinker, Alon D Altman, Marcus Q Bernardini, et al.
Gynecologic Oncology|February 11, 2024
High grade adverse event reporting and enrolment in gynecologic oncology clinical trialsAinhoa Madariaga, Heather Cole, Tyler Pittman, et al.
Journal of Translational Medicine|April 3, 2016
A phase I study of high-dose rosuvastatin with standard dose erlotinib in patients with advanced solid malignanciesGlenwood D Goss, Derek J Jonker, Scott A Laurie, et al.
Cold Spring Harbor Molecular Case Studies|December 15, 2019
Heterogeneous alteration of the ERBB3-MYC axis associated with MEK inhibitor resistance in a <i>KRAS</i>-mutated low-grade serous ovarian cancer patientIlaria Colombo, Swati Garg, Arnavaz Danesh, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|December 21, 2010
Evaluation of pandemic H1N1 (2009) influenza vaccine in adults with solid tumor and hematological malignancies on active systemic treatmentHelen J Mackay, Jacob McGee, Diego Villa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 17, 2015
Randomized Phase II Trial of Ridaforolimus in Advanced Endometrial CarcinomaAmit M Oza, Sandro Pignata, Andres Poveda, et al.
Pageof 25

Showing results (81-90 of 250) with videos related to

Sort By:
Pageof 25
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 19, 2019
FIGO 2018 stage IB2 (2-4 cm) Cervical cancer treated with Neo-adjuvant chemotherapy followed by fertility Sparing Surgery (CONTESSA); Neo-Adjuvant Chemotherapy and Conservative Surgery in Cervical Cancer to Preserve Fertility (NEOCON-F). A PMHC, DGOG, GCIG/CCRN and multicenter studyMarie Plante, Nienke van Trommel, Stephanie Lheureux, et al.
Investigational New Drugs|March 15, 2011
A phase II trial of the Src kinase inhibitor saracatinib (AZD0530) in patients with metastatic or locally advanced gastric or gastro esophageal junction (GEJ) adenocarcinoma: a trial of the PMH phase II consortiumHelen J Mackay, Heather J Au, Elaine McWhirter, et al.
Anti-Cancer Drugs|December 1, 2005
Phase I trial of gemcitabine, doxorubicin and cisplatin (GAP) in patients with advanced solid tumorsIgnacio Duran, Lillian L Siu, Eric X Chen, et al.
Gynecologic Oncology Reports|March 15, 2021
Can <i>TP53</i> variant negative be high-grade serous ovarian carcinoma? A case seriesLawrence Kasherman, Swati Garg, Nairi Tchrakian, et al.
Current Oncology (Toronto, Ont.)|June 23, 2022
A Pan-Canadian Consensus Statement on First-Line PARP Inhibitor Maintenance for Advanced, High-Grade Serous and Endometrioid Tubal, Ovarian, and Primary Peritoneal CancersAnna V Tinker, Alon D Altman, Marcus Q Bernardini, et al.
Gynecologic Oncology|February 11, 2024
High grade adverse event reporting and enrolment in gynecologic oncology clinical trialsAinhoa Madariaga, Heather Cole, Tyler Pittman, et al.
Journal of Translational Medicine|April 3, 2016
A phase I study of high-dose rosuvastatin with standard dose erlotinib in patients with advanced solid malignanciesGlenwood D Goss, Derek J Jonker, Scott A Laurie, et al.
Cold Spring Harbor Molecular Case Studies|December 15, 2019
Heterogeneous alteration of the ERBB3-MYC axis associated with MEK inhibitor resistance in a <i>KRAS</i>-mutated low-grade serous ovarian cancer patientIlaria Colombo, Swati Garg, Arnavaz Danesh, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|December 21, 2010
Evaluation of pandemic H1N1 (2009) influenza vaccine in adults with solid tumor and hematological malignancies on active systemic treatmentHelen J Mackay, Jacob McGee, Diego Villa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 17, 2015
Randomized Phase II Trial of Ridaforolimus in Advanced Endometrial CarcinomaAmit M Oza, Sandro Pignata, Andres Poveda, et al.
Pageof 25